drugset
Drugs / TDaP-IPV vaccine
last change Jan 2020 re-read 9 days ago

TDaP-IPV vaccine

also known as Boostrix Polio · tetanus-diphtheria-pertussis inactivated polio vaccine

Vaccine

Developed for
pertussis
Investigated by
Emory University · International AIDS Vaccine Initiative · Radboud University Medical Center · University of Southern Denmark · Zambia-Emory HIV Research Project

Trials 2

today NCT02589678 · Ph 1/2 NCT02771782 · Ph 4
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02589678 Aug 2015 → May 2017 — Emory University Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02771782 Jan 2015 → Jul 2016 pertussis Radboud University Medical Center Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TDaP-IPV vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02771782 ↗
1

NCT02589678 ↗
Known as Boostrix Polio “Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular” NCT02771782 ↗
Known as tetanus-diphtheria-pertussis inactivated polio vaccine “We randomized 75 healthy, female, adult volunteers to receive either BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3 months...” PMID 30919883 ↗ Jan 2020
Modality Vaccine “Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine” NCT02589678 ↗
Route Intramuscular “will be administered intramuscularly” NCT02589678 ↗